Combinatorial chemistry in conjunction with High Throughput Screening(HTS) is revolutionizing the drug discovery process. Yet, we have muchto learn about the integration of these powerful techniques withinformation from genomics, proteomics, computation and pharmacokineticsbefore dramatic increases in the drug discovery/development processescan be achieved. The chapters in this book represent the state of theart regarding the integration of combinatorial chemistry and HTS inconnection with anti-inflammatory targets. Obviously, there is much workto be done beyond what is described in this text, nevertheless, itshould set the stage for creative thinking among scientists of manydisciplines for the accomplishment of our ultimate goals in treatinginflammatory diseases. Contents. List of Contributors. Intoduction. Sharon M. Dankwardt: Solid phase synthesis: applications to combinatorial libraries. Mohamed A. Iqbal and Mark A. Ator: Proteaspme inhibitors. Tariq Ghayur, Sheryl J. Hays and Robert V. Talanian: Caspase-1 (ICE) and other caspases as drug discovery targets: opportunities and progress. William A. Metz and Norton P. Peet: Elastase inhibitors. M. Anthony Leesnitzer, D. Mark Bickett, Marcia L. Moss and J. David Becherer: A high-throughput assay for the TNF conerting enzyme. Kenneth D. Rice and William R. Moore: Tryptase inhibitors. Falguni Dasgupta: Selectin antagonists. Kerry W. Fowler and David T. Crowe: Cell adhesion integrins as pharmaceutical targets. Brion W. Murray, Yoshitaka Satoh and Bernd Stein: Inhibitors of the MAPK pathway. Mark J. Suto and Anthony M. Manning: Inhibition of NF-kB. Terry L. Bowlin, Stephen D. Yanofsky and Herman Schreuder: IL-1 antagonist discovery. Mark A. Giembycz: Phosphodiesterase inhibitors for respiratory disease. Subject index
